Metabolic Fate of the Sympathoneural Imaging Agent 6-[18F]Fluorodopamine in Humans
Authors:
- D. S. GoldsteinDGD. S. Goldstein
- C. HolmesCHC. Holmes
- 1 January 1997
- journal article
- Published by Taylor & Francis in Clinical and Experimental Hypertension
- Vol. 19 (1-2) , 155-161
Abstract
We examined the metabolism of 6-[18F]fluorodopamine, by assaying arterial plasma concentrations of radioactivity, 6-[18F]fluorodopamine, and 6-[18F]fluorodopamine metabolites in untreated subjects or subjects given desipramine to block neuronal uptake of catecholamines or tyramine to displace vesicular amines. After the 3-min 6-[18F]fluorodopamine infusion, plasma 6-[18F]fluorodopamine levels declined precipitously, total radioactivity declining slowly. After 30 min, the main identified metabolite was 6-[18F]fluorodopamine-sulfate. Desipramine attenuated the rapid increase in plasma 6-[18F]fluorodihydroxyphenylacetic acid levels, and tyramine briefly increased 6-[18F]fluorodopamine levels. Neither drug affected 6-[18F]fluorodopamine-sulfate levels. The results indicate that soon after 6-[18F]fluorodopamine infusion, plasma radioactivity corresponds mainly to 6-[18F]fluorodopamine metabolites; that sympathetic nerves rapidly remove 6-[18F]fluorodopamine, which then undergoes oxidative deamination in the neuronal cytoplasm and sequestration in sympathetic vesicles; and that sulfoconjugation of [18F]fluorodopamine occurs extraneuronally.Keywords
This publication has 3 references indexed in Scilit:
- Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1994
- Positron emission tomographic imaging of cardiac sympathetic Innervation using 6-[ 18 F]Fluorodopamine: Initial findings in humansJACC, 1993
- Positron emission tomographic imaging of cardiac sympathetic innervation and function.Circulation, 1990